Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1016

Sort by

Sort Order Select

Journal Articles

Timing the Initiation of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 573.

https://doi.org/10.1182/blood-2019-124357

Published: 2019

Journal Articles

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Veronica A Guerra, MD, Yan Yuanqing, PhD, Joanne Hsu, BS, Feng Wang, PhD, Mansour Alfayez, MD, Kiyomi Morita, MD, Xingzhi Song, PhD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Guillermo Montalban Bravo, MD, Jianhua Zhang, PhD, Latasha Little, BS, Curtis Gumbs, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 458.

https://doi.org/10.1182/blood-2019-127498

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1839.

https://doi.org/10.1182/blood-2019-124828

Published: 2019

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1904.

https://doi.org/10.1182/blood-2019-131478

Published: 2019

Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD

Blood (2019) 134 (Supplement_1): 1848.

https://doi.org/10.1182/blood-2019-127893

Published: 2019

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Mengyang Di, MD PhD, Thomas A Ollila, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3477.

https://doi.org/10.1182/blood-2019-121959

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Blood (2019) 134 (Supplement_1): 1503.

https://doi.org/10.1182/blood-2019-126459

Published: 2019

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

María-Victoria Mateos, MD PhD, Albert Oriol, MD, Alessandra Larocca, Paula Rodriguez Otero, Joan Bladé, MD, Michele Cavo, Hani Hassoun, MD, Xavier Leleu, MD PhD, Adrián Alegre Amor, MD, Christopher Maisel, MD, Agne Paner, MD, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Sara Thuresson, MSc, Hanan Zubair, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1883.

https://doi.org/10.1182/blood-2019-124825

Published: 2019

Journal Articles

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Michelle A. Roesler, BS, Amy Linabery, PhD MS, Michaela Richardson, MPH, Adina Cioc, MD, Betsy A Hirsch, PhD, Phuong L. Nguyen, MD, Erica D. Warlick, MD, Jenny Poynter, PhD

Blood (2019) 134 (Supplement_1): 3014.

https://doi.org/10.1182/blood-2019-130940

Published: 2019

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Bachisio Ziccheddu, PhD, Giulia Biancon, Chiara De Philippis, MD, Filippo Bagnoli, MD, Francesco Maura, MD, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, PhD, Eftathios Kastritis, Meletios A. Dimopoulos, MD, Michele Cavo, Cristiana Carniti, PhD, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli, MD PhD

Blood (2019) 134 (Supplement_1): 3056.

https://doi.org/10.1182/blood-2019-122197

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

NARROW

Timing the Initiation of Multiple Myeloma

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only